Subscribe to RSS
DOI: 10.1055/s-0042-101032
In Vitro Metabolic Stability and Permeability of Gymnemagenin and Its In Vivo Pharmacokinetic Correlation in Rats – A Pilot Study
Publication History
received 27 August 2015
revised 12 December 2015
accepted 18 December 2015
Publication Date:
25 February 2016 (online)
![](https://www.thieme-connect.de/media/plantamedica/201606/lookinside/thumbnails/10-1055-s-0042-101032_pmz0846-1.jpg)
Abstract
Gymnema sylvestre is traditionally used for diabetes mellitus. A literature survey revealed very few reports, particularly on rat liver microsomal stability, caco-2 permeability and efflux concerns and its correlation with the bioavailability of gymnemagenin, an important component of G. sylvestre. Therefore, the objective of our study was to investigate the in vitro rat liver microsomal stability and caco-2 permeability along with the efflux of gymnemagenin and establish a probable correlation of these in vitro findings with pharmacokinetic parameters after oral and intravenous administration in rats.
Rat liver microsomal stability studies to estimate the in vitro intrinsic half-life, clearance, and Caco-2 permeability after 21 days of culture to determine the apparent permeability from apical to basal and from basal to apical, and efflux ratio of gymnemagenin were performed using liquid chromatography-tandem mass spectrometry. A sensitive, robust bioanalytical method was validated and successfully applied to determine the plasma exposure of gymnemagenin.
In vitro rat liver microsomal stability demonstrated that gymnemagenin metabolizes rapidly with a short apparent and intrinsic half-life (~ 7 min) and high intrinsic clearance, i.e., 190.08 µL/min/mg of microsomes. The results of the Caco-2 study indicated a poor permeability (1.31 × 10− 6 cm/sec) with a very high efflux ratio. The pharmacokinetic study revealed poor oral bioavailability (~ 14 %) of gymnemagenin and it was found to have a short half-life and a high clearance in rats. Our in vitro findings indicated low metabolic stability and poor Caco-2 permeability with high efflux, which might have a role in the observed poor oral bioavailability in rats.
Key words
Gymnema sylvestre - Asclepiadaceae - gymnemagenin - rlm - Caco-2 - pharmacokinetics - LC-MS/MS-
References
- 1 Mitra SK, Gopumadhavan S, Muralidhar TS, Anturlikar SD, Sujatha MB. Effect of D-400 herbomineral preparation on lipid profile glycated haemoglobin and glucose tolerance in streptozotocin induced diabetes in rats. Indian J Exp Biol 1995; 33: 798-800
- 2 Ye WC, Zhang Q, Liu X, Che C, Zhao S. Oleanane saponins from Gymnema sylvestre . Phytochemistry 2000; 53: 893-899
- 3 Bakrudeen AAH, Rao AS, Rao MV, Tahil RM. Different wavelengths light to induce physiological changes callus for the biosynthesis of gymnemic acid in Gymnema sylvestre . Food Tech 2012; 23: 31-34
- 4 Kanetkar PV, Singhal RS, Laddha KS, Kamat MY. Extraction and quantification of gymnemic acids through gymnemagenin from callus cultures of Gymnema sylvestre . Phytochem Anal 2006; 17: 409-413
- 5 Trivedi PD, Pundarikakshudu K, Shah K. A validated reverse phase liquid chromatographic method for quantification of gymnemagenin in the Gymnema sylvestre R. Br. leaf samples, extract and market formulation. IJASE 2011; 9: 25-31
- 6 Tiwari P, Mishra BN, Sangwan NS. Phytochemical and pharmacological properties of Gymnema sylvestre: an important medicinal plant. Biomed Res Int 2014; 2014: 830285
- 7 Kerns EH, Di L. Drug-like properties: concepts, structure design, and methods – from ADME to toxicity optimization. Amsterdam: Academic Press; 2008: 136-164
- 8 Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, McIntyre F, Rance DJ, Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro data. J Pharmacol Exp Ther 1997; 283: 46-58
- 9 Chetan SK, Natalie DE, Tushar SG, Paul OG, Thomas CD. Evaluation of drug P-glyprotein-mediated renal drug interaction in an MDR1-MDCK model. Pharmacotherapy 2003; 23: 436-442
- 10 Artursson P, Karlsson J. Correlation between oral absorption in human and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175: 880-885
- 11 Grès MC, Jullian B, Bourrié M, Meunier V, Roques C, Berger M, Boulenc X, Berger Y, Fabre G. Correlation between oral drug absorption in human and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line. Pharm Res 1998; 15: 726-733
- 12 Bhagyashree K, Ankur G, Dada P, Laxman K, Shirish J, Ismail M, Basavan D. Determination of gymnemagenin in rat plasma using high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics after oral administration of Gymnema sylvestre extract. Biomed Chromatogr 2013; 27: 669-675
- 13 Food and Drug Administration of the United States. Guidance for Industry – Bioanalytical Method Validation; May 2001. Available at. http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf Accessed March 18, 2014
- 14 Hazra A, Mondal C, Chakraborty D, Halder AK, Bharitkar YP, Mondal SK, Banerjee S, Jha T, Mondal NB. Towards the development of anticancer drugs from andrographolide: semisynthesis, bioequivalence, QSAR analysis and pharmacokinetic studies. Curr Top Med Chem 2015; 15: 1013-1026
- 15 Kratz JM, Teixeira MR, Koester LS, Simões CM. An HPLC-UV method for the measurement of permeability of marker drugs in the Caco-2 cell assay. Braz J Med Biol Res 2011; 44: 531-537
- 16 Garberg P, Eriksson P, Schipper N, Sjöström B. Automated absorption assessment using Caco-2 cell cultured on both sides of polycarbonate membranes. Pharm Res 1999; 16: 441-445
- 17 Fagerholm U, Johansson M, Lennernäs H. Comparison between permeability coefficients in rats and human jejunum. Pharm Res 1996; 13: 1336-1342
- 18 Houston JB, Kenworthy KE, Galetin A. Typical and atypical enzyme kinetics. In: Lee JS, Obach RS, Fisher MB, editors Drug metabolizing enzymes: cytochrome P450 and other enzymes in drug discovery and development. Boca Raton, FL: CRC Press; 2003: 211-254
- 19 Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999; 27: 1350-1359
- 20 Polli JE, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabit-Singh CO. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 2001; 299: 620-628
- 21 Higers AR, Conradi RA, Burton PS. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm Res 1990; 7: 902-910
- 22 Di L, Kerns EH, Hong Y, Kleintop TA, McConnell OJ, Huryn DM. Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates. J Biomol Screen 2003; 8: 453-462
- 23 Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003; 75: 3019-3030